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A B S T R A C T
A simple, precise, stability indicating RP-HPLC method was developed and validated for de-
termination of Temozolomide (TMZ) in bulk sample and nanostructured lipid carriers. A Box–
Behnken statistical design with three factors and three levels was employed to optimize
the chromatographic conditions. The separation was achieved using solvent system com-
bination using methanol: water (30:70) with acetic acid (0.25%). The developed method was
validated for linearity, precision, accuracy, limit of detection and limit of quantitation, and
robustness in accordance with the ICH guidelines. Further degradation study of TMZ in dif-
ferent stress conditions was studied. The method was found linear with regression co-
efficient of 0.999 over a wide range of 10–100 μg/mL. All the validation parameters were found
to be within the acceptance range. The developed method was successfully applied to es-
timate the amount of TMZ in pharmaceutical formulations.
© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open









Temozolomide (Fig. 1) (3,4-dihydro-3-methyl-4-oxoimidazo-
[5,1-d]-astetrazine-8-carboxamide) is an oral alkylating agent
of imidazotetrazine class which is used in the treatment of ana-
plastic astrocytoma, glioblastoma multiforme and malignant
metastatic melanoma (Danson et al., 2003; Friedman et al.,
2000). It is used alone in the treatment of aforementioned
tumors, but its efficacy in combination with other cytotoxic
agents like Paclitaxel (Ni et al., 2014), interferon alfa-2b
(Kottschade et al., 2013), thalidomide (Baumann et al., 2004)
and bevacizumab (Middleton et al., 2000 18) has also been re-
ported. TMZ itself is unstable and undergoes chemical
degradation at a physiological pH to active metabolite MTIC
5-(-3-Methyltrizen-1-yl) imidazole-4-carboxamide and further
to AIC (4-amino-5-Imidazole carboxamide). There are many lit-
eratures available on TMZ that deal mainly with the estimation
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in biological fluid (Ostermann et al., 2004; Shen et al., 1995).
Many analytical techniques such as LC/MS/MS (Chowdhury
et al., 1999), miceller electrokinetic capillary chromatography
(Andrasi et al., 2010), HPLC (Razak et al., 2013) and MS detec-
tors employed to analyze the stability of the TMZ. There are
several types of experimental design methodologies suitable
for experiments with at least two independent variables (Alves
and Scarminio, 2007; Beg et al., 2015). The utility of experi-
mental design methodology analytical methods has been
reported for drugs like voriconazole (Srinubabu et al., 2007),
amoxicillin trihydrate (Beg et al., 2012), lenalidomide (Hasnain
et al., 2013), risperidone (Imam et al., 2014). As there was no
report of optimized analytical method for TMZ using design
of experiment technique was reported. It was envisaged to
develop and validate a simple and robust analytical method
to quantify TMZ by HPLC using Design Expert software (Version
8.0.5; Stat-Ease Inc., Minneapolis, Minnesota). A special atten-
tion was paid to the determination and separation of TMZ from
its degradation metabolites by predicting its stability in dif-




Temozolomide (purity: 99.8%) was obtained as a gift sample from
Natco Pharma Ltd (Dehradun, India). Marketed Capsule formu-
lation (Temonat, Natco Pharma Ltd, Hyderabad) containing 20 mg
of TMZ was purchased from a local pharmacy. HPLC grade
methanol and water were purchased from Merck India. Glacial
acetic acid and other solvents used were of analytical grade.
2.2. Equipment and chromatographic conditions
HPLC analysis was carried out on Shimadzu system (soft-
ware: VP 5.032, Shimadzu, Tokyo, Japan) consisted of a binary
pump and UV detector SPD-10A VP. Rheodyne injection valve
with a 25 μL loop used for injection of the samples and the chro-
matographic separation was carried out in C-18 column
(150 mm × 4.6 mm i.d., 5 μm particle size; Shiseido, Japan). The
mobile phase that consisted of methanol and water (contain-
ing acetic acid 0.25%) in different ratio was used. The freshly
prepared mobile phase was filtered through a 0.20 μm pore size
nylon membrane filter and pumped in an isocratic mode with
a flow rate of 1 mL/min. The elution of the analyte was moni-
tored at a wavelength of 330 nm.
2.3. Preparation of calibration curve
The stock solution was prepared by dissolving an accurately
weighed 10 mg of TMZ in the mobile phase in a 10 mL volu-
metric flask. The volume was made up to 10 mL with the same
solvent to give a concentration of 1 mg/mL. From this stock so-
lution a concentration range of 10–100 μg/mL was prepared
upon its further serial dilution. All the samples prepared were
filtered through a 0.20 μm pore size filter before analysis.
2.4. Optimization
The mobile phase comprising mixture of methanol and water
in acetic acid with flow rate of 1 mL/min was selected from
preliminary studies. The concentration of mobile phase com-
ponents viz. methanol (X1), acetic acid (X2) and flow rate (X3)
were selected as independent variable, whereas peak area (Y1)
and retention time (Y2) were chosen as response variable for
experimental design. The design showing a total of 17 experi-
mental runs with five center points obtained from the design
matrix was subjected to laboratory experiment to generate the
response variables as summarized in Table 1. Statistical analy-
sis was performed using ANOVA to compute the significant
difference in the mobile phase composition obtained from the
design matrix. The response surface methodology was em-
ployed to analyze the effect of independent variables on the
responses. Finally, optimum mobile phase composition was
traded-off using the numerical and graphical optimization pro-
cedure (Singh et al., 2005).
2.5. Analysis of TMZ in marketed dosage form
Twenty capsules (20 mg) were taken, and powder was col-
lected and weighed. An accurately weighed portion of the
powder equivalent to 50 mg of TMZ was taken in 50 mL volu-
metric flask. About 30 mL of methanol was added to this flask
and sonicated in an ultrasonic bath for 3 min. This solution
was then diluted, and then filtered through 0.2 μm nylon filter.
Fig. 1 – Chemical structure of temozolomide.
Table 1 – Design of experiment based design matrix
using dependent variables with their independent





(X1) (X2) (X3) (Y1) (Y2)
1. 15 0.45 1 4.015 2,975,371
2. 45 0.25 1.25 5.1 2,176,514
3. 30 0.25 1 3.875 2,259,136
4. 15 0.25 0.75 3.982 2,587,469
5. 45 0.25 0.75 5.23 2,475,993
6. 45 0.45 1 6.1 2,776,557
7. 30 0.25 1 3.875 2,152,468
8. 15 0.05 1 4.75 1,976,018
9. 30 0.25 1 3.875 2,159,785
10. 45 0.05 1 5.67 2,176,645
11. 30 0.25 1 3.875 2,166,448
12. 30 0.25 1 3.875 2,157,865
13. 30 0.45 0.75 4.125 2,968,753
14. 15 0.25 1.25 3.983 2,166,748
15. 30 0.05 1.25 4.25 1,898,453
16. 30 0.05 0.75 4.23 1,967,453
17. 30 0.45 1.25 4.5 2,967,456
X1, methanol (%); X2, acetic acid (%); X3, flow rate (mL/min); Y1, re-
tention time (minute); Y2, peak area.
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The filtrate was collected and 5 mL of the filtrate was trans-
ferred to volumetric flask, diluted to desired volume.
2.6. Forced degradation studies
Stress testing of the drug substance can help identify the likely
degradation products, the stability of the molecule and also
validate the stability and specificity of the analytical proce-
dures (ICH, 1997).
2.6.1. Acidic and alkaline degradation studies
Ten milligram of TMZ was dissolved in methanol in a 10 mL
volumetric flask and volume was made up to 10 mL with 0.1 M
HCL and 0.1 M NAOH separately to give a strength of 1000 μg/
mL. The solutions were refluxed over 8 hours on a water bath
at 80 °C. The resultant solutions were neutralized with 0.1 M
NAOH and 0.1 M HCL. Further the resultant mixtures were
diluted with methanol:water (1:1) to give 50 μg/mL of concen-
tration, and final solution was injected for analysis.
2.6.2. Neutral degradation studies
Ten milligram of TMZ was dissolved in methanol in a 10 mL
volumetric flask to give 1000 μg/mL of concentration. The re-
sultant solution was refluxed and processed in the same way
as in alkaline and acidic degradation studies. The sample was
diluted with methanol:water (1:1) to 50 μg/mL concentration
and final solution was injected for analysis.
2.6.3. Oxidative degradation studies
Ten milligram of TMZ was dissolved in methanol in a 10 mL
volumetric flask and volume made up to 10 mL with 3% hy-
drogen peroxide to give 1000 μg/mL of concentration. The
resultant solution was refluxed, diluted to a concentration of
50 μg/mL and injected for analysis.
2.6.4. Thermal degradation studies
Ten milligram of TMZ was kept in an oven at 100 °C for 24 hrs.
The dried sample was dissolved in methanol in the volumet-
ric flask and the volume made up to 10 mL with methanol:water
(1:1). The resultant solution was refluxed over 8 hrs in a water
bath at 80 °C and diluted to 50 μg/mL of concentration, and final
solution was injected for analysis.
2.6.5. Photolytic degradation studies
TMZ was subjected for photolytic degradation at 260 nm in the
UV chamber for 24 hrs with further exposure in sunlight for
another 24 hrs. A fraction of ten milligram from exposed sample
was dissolved in methanol and volume made up to 10 mL with
methanol:water (1:1) and further diluted to 50 μg/mL of con-
centration, and final solution was injected for analysis.
2.7. Validation study
The developed method was validated in accordance with the
ICH guidelines (ICH, 1997).
2.7.1. System suitability
The system suitability was assessed by injecting six replicate
of drug solution at a concentration of 10 μg/mL. The accep-
tance criteria considered for the system suitability was taken
as ±2% for the percent coefficient of variation (%CV) of the peak
area and retention time.
2.7.2. Accuracy and precision
Inter-day precision refers to the use of the analytical proce-
dure within a laboratory over a short period of time during the
same day. Intra-day precision was assessed by comparing the
assays on three different days. For both inter-day and intra-
day precision determination, three different concentrations of
TMZ (20, 40 and 80 μg/mL) were injected to evaluate the mean,
standard deviation and relative standard deviation of the peak
areas to their corresponding drug concentration.
2.7.3. Robustness
The proposed method was evaluated by introducing some small
deliberate changes in the chromatographic conditions such as
mobile phase composition i.e. pH of the solvent (±0.5), flow rate
(±0.25%) and concentration of water (±5%). The effect of each
variable on retention time was evaluated individually.
3. Results
3.1. Experimental design optimization
To identify the robust and optimized mobile phase composi-
tion the positive and/or negative interactions among the
independent variables were traded off. Fig. 2(A and B) por-
trays the response surfaces and depict the relationship between
the independent variables methanol (X1), acetic acid (X2), and
pH (X3) on dependent variables i.e., peak area (Y1) and reten-
tion time (Y2). It has been observed that the response variable
(Y1) is dependent on the concentration of methanol and acetic
acid as the influential. A curvilinear plot (Fig. 2A) was ob-
tained indicating proportionate increase in peak area with
increasing concentration of methanol and acetic acid, whereas
gradual increase in flow rate of mobile phase leads to de-
crease in peak area. Similarly, the retention time (Y2) was found
to be dependent on the concentration of methanol alone as
influential factors in the mobile phase composition. A non-
linear relationship (Fig. 2B), where the Rt was proportionately
decreased at initial levels and then increasing trend with in-
creasing concentration of acetic acid was observed in the mobile
phase mixture. However, flow rate was found to be less influ-
ential in affecting the responses parameters i.e., peak area and
retention time. Among the various models, the classical second-
degree model with a quadratic experimental domain was
suggested by the design with the highest least squares regres-
sion value for response Y1 (r2 = 0.9858) and response Y2
(r2 = 0.9581) as compared to other models. For better under-
standing of the effect of interaction among the independent
variables and responses linear polynomial equations were
studied. The linear polynomial equations generated from
ANOVA are depicted below:
Retention time Y1( ) −= + −
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From the polynomial equations, it has been observed that
all three independent variables with a positive sign indicates
positive effect on both the observed responses and negative
sign showed negative effect on both the observed responses.
However for retention time (Y1) the two of the interaction terms
were found to be positive i.e., the combined effect of metha-
nol (X1) and acetic acid (X2), and acetic acid (X2) and flow rate
(X3), whereas the combined effect of methanol (X1) and flow
rate (X3) showed negative effect on retention time.
However for response peak area (Y2), the two of interac-
tion terms were found to be negative i.e., methanol (X1) and
acetic acid (X2), and methanol (X1) and flow rate (X3), whereas
positive effect was shown by combined effect of acetic acid (X2)
and flow rate (X3).
3.2. Method validation
3.2.1. System suitability
The %CV of peak area and retention time for TMZ was found
to be within 2% indicating the suitability of the system. The
number of theoretical plates and USP tailing factor for the six
replicate injections were found to be 8965.5 ± 1.7% and
1.18 ± 0.2% respectively.
3.2.2. Linearity and range
The standard calibration plot demonstrated a good relation-
ship between concentration of TMZ and area of the
chromatogram over a range of 10–100 μg/mL with regression
coefficient of 0.99. The LOD and LOQ of the developed method
were 2.01 and 6.11 μg/mL which showed that the method was
sensitive to detect and quantitate the TMZ. Statistical data for
regression analysis are summarized in Table 2.
Fig. 2 – 3D-response surface plots showing the influence of independent variables on peak area and retention time for the
TMZ.
Table 2 – Summary of linear regression data obtained
from design of experiment based design matrix.
Statistical parameter HPLC
Linearity range (μg/mL) 10–100
Regression equation y = 30,100x − 64,291
Correlation coefficient 0.999
Slope ± SD 30,099.3333 ± 112.491481
Intercept ± SD 64,291 ± 1359.8886
% RSD of slope 0.373
% RSD of intercept 2.11
Limit of detection (μg/mL) 2.019
Limit of quantitation (μg/mL) 6.119
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3.2.3. Accuracy and precision
The percentage recovery was found to be in the range of 99.66–
100.56. The % RSD for recovery value is less than 2 which in
turn indicates the method was accurate by satisfying the ac-
ceptance criteria (Table 3).The % RSD for inter-day precision
and for intra-day precision was found to be in the range of 0.16–
0.67 and 0.66–0.86 respectively. The developed method showed
good precision and reproducibility with % RSD found to be less
than 2 are listed in Table 4.
3.2.4. Robustness
No significant effect was observed on retention time and area,
when small deliberate changes were made to chromato-
graphic conditions. The results are presented in Table 5 along
with system suitability parameters of normal methodology.The
influence of each variable on retention time of TMZ was in-
significant with % RSD > 2% implying the robustness of the
method.
3.2.5. Forced degradation studies
Forced degradation studies were carried out by exposing the
TMZ sample to 0.1 M HCL, 0.1 M NAOH, 3% H202, dry heat, hu-
midity and UV light. The degradation peaks obtained were
distinguishable from the parent peak. There was not any sig-
nificant change in the retention time of TMZ but decrease in
areas due to degradation metabolites eluted at different time
points was observed. The sample subjected to acidic stress
showed parent peak at 3.83 min but a slight decrease in area
was observed due to degradation of the parent drug in acidic
condition. In acidic stress condition the retention time of the
metabolite peak was found to be 2.80 minutes and % recov-
ery of 95.5% (Fig. 3A). TMZ sample kept under alkaline stress
condition showed an intense metabolite peak at 3.042 minutes
as it was highly unstable under alkaline stress condition with
recovery decreased to 59.6% (Fig. 3B). TMZ sample was kept in
an oven at 100 °C for 24 hours and diluted sample upon in-
jection showed the peak of degradation metabolite as shown
in Fig. 3(D) at 2.80 min along with the parent peak (RT: 3.827)
with recovery of 72.3%. TMZ sample was stable under humid-
ity and UV stress with % recovery of 99.6% (Fig. 3C and F). It
was slightly unstable under oxidative stresses with % recov-
ery of 94.1% (Fig. 3E). Retention times of parent as well as
degradation metabolites with recoveries are summarized in
Table 6 and Fig. 3(A–E).
4. Discussion
The method was optimized by the design of experiment meth-
odology which also furnished thought-thorough understanding
of the factor–response relationship and underlying interac-
tions among them. The search for optimum condition was
carried out by numerical optimization by ‘trading off’ various
factors to attain the desired goals, that is maximization of peak
area and theoretical plates and minimization of retention time
and peak tailing to obtain desirability function closer to 1. The
optimized condition showed mobile phase composition con-
taining methanol (35%), acetic acid (0.3%) and flow rate (1 mL/
min). The graphical optimization also yielded the optimum
Table 3 – Accuracy study data of the developed TMZ HPLC method at optimized chromatographic condition.





(n = 3) ± SD
%RSD
0 50 49.91 99.83 ± 0.34 0.34
50 75 74.75 99.66 ± 1.151 1.15
100 100 100.08 100.18 ± 1.18 1.19
150 125 125.14 100.56 ± 1.19 1.21
Gel formulation
50 49.4 98.9 ± 1.67 1.68
Marketed dosage form
50 49.2 98.7 ± 2.32 2.35
Table 4 – Intra-day and inter-day precision study data of














20 19.7 ± 0.11 0.532 19.55 ± 0.08 0.41
40 39.8 ± 0.22 0.562 38.1 ± 0.27 0.67
80 79.5 ± 0.67 0.827 78.5 ± 0.28 0.35
Reproducibility of method
20 18.9 ± 0.21 1.119 19.6 ± 0.098 0.73
40 39.2 ± 0.59 1.516 39.9 ± 0.341 0.86
80 77.3 ± 1.08 1.404 76.6 ± 0.514 0.66
Table 5 – Robustness study data of the developed TMZ









7.1 3.87 ± 0.023 0.471 6.8
6.8 3.88 ± 0.019 0.328
6.5 3.87 ± 0.029 0.495
Flow rate (mL/min)
0.75 3.88 ± 0.010 0.457 1
1 3.87 ± 0.023 0.324
1.25 3.89 ± 0.037 0.315
% Water
75 3.89 ± 0.045 0.585 70
70 3.88 ± 0.091 0.324
80 3.91 ± 0.014 0.315
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solution demarcated within the analytical design space as
shown in chromatogram of TMZ (Fig. 4A). A retention time (Rt)
of 3.91 min was observed with a reasonable peak area within
the defined limits. The analysis of system suitability test dem-
onstrated that the developed chromatographic conditions were
able to provide accurate data. The method was found to be
precise (both intra-day and inter-day precision) and the results
showed the repeatability of the method for the analysis of TMZ
in developed formulation. The obtained results for percent-
age recovery of TMZ reference substance from formulation
showed that the proposed method was accurate and the results
were found to be within acceptance range. The result of ro-
bustness study showed that no significant effect was observed
on retention time and area, when small deliberate changes were
made to chromatographic conditions. There was not any sig-
nificant change in the retention time of TMZ but decrease in
area due to degradation metabolites eluted at different time
points was observed.The degradation peaks obtained were dis-
tinguishable from the parent peak. The method was highly
advantageous vis-a’-vis in terms of time economy for deter-
mination of TMZ formed during stress conditions, as is evident
from low Rt values of the DPs.The developed method was found
to be sensitive which was evaluated in terms of LOD and LOQ.
Further, the Rt of TMZ in all the dosage forms was similar with
respect to the standard TMZ without any significant differ-
ence in the standard solution. Other parameters, like theoretical
plates and peak tailing were found to be within the accept-
able limits. This is a corroborated high degree of utility of
Fig. 3 – HPLC chromatograms of TMZ (A), TMZ API (B), TMZ peak in NLC based gel (C), and TMZ peak in marketed dosage
form.





% RSD RT of degradation
products
% RSD % Recovery
after 24 hrs
Acidic 3.835 ± 0.003 0.079 2.808 ± 0.008 0.287 95.5
Alkaline 3.916 ± 0.004 0.103 3.044 ± 0.004 0.143 59.6
Neutral 3.933 ± 0.003 0.089 3.594 ± 0.003 0.105 87.7
Oxidative 3.857 ± 0.002 0.065 2.823 ± 0.006 0.230 94.17
Thermal 3.827 ± 0.004 0.120 2.808 ± 0.007 0.276 72.3
Photolytic 3.887 ± 0.001 0.002 0.00 0.00 99.6
Fig. 4 – Forced degradation chromatograms of TMZ (A) acidic stress, (B) alkaline stress, (C) oxidation stress, (D) thermal
stress, (E) neutral stress and (F) photolytic stress.
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developed method for routine estimation of TMZ in pharma-
ceutical formulations.
5. Conclusions
Further, the method was optimized by design of experiment
optimization technique using different variables. The mea-
sured signal was shown to be precise, accurate, and linear over
the concentration range tested with a correlation coefficient
better than 0.99. Moreover, the lower solvent consumption along
with the short analytical run time of 3.8 min leads to a cost
effective and environmentally friendly chromatographic pro-
cedure. The forced degradation studies showed well separation
of parent peak from degradation metabolites. Thus, the above
validated method is rapid, selective, specific, and accurate can
be used for the separation of impurities and quantitative de-
termination of TMZ in API and pharmaceutical formulations.
The method demonstrated high degree of practical utility for
estimation of TMZ in pharmaceutical dosage forms.
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